Ocular Therapeutix (OCUL) Q1 2024 Earnings
OCUL·Reported May 7, 2024·Before market open
Ocular Therapeutix reported Q1 2024 revenue of $14.7M, missed analyst consensus of $15.4M by $695.0K. Diluted EPS came in at $-0.24, missed the $-0.18 consensus by $0.06.
Revenue
$14.7Mmissed by $695.0K
Consensus: $15.4MDiluted EPS
$-0.24missed by $0.06
Consensus: $-0.18
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Ocular Therapeutix's Q1 2024 earnings report.
Ocular Therapeutix (OCUL) reported Q1 2024 earnings on May 7, 2024 before market open.
Ocular Therapeutix reported revenue of $14.7M and diluted EPS of $-0.24 for Q1 2024.
Revenue missed the consensus estimate of $15.4M by $695.0K. EPS missed the consensus estimate of $-0.18 by $0.06.
You can read the 10-Q periodic report (0001558370-24-007065) directly on SEC EDGAR. The filing index links above go to sec.gov.